BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11070938)

  • 1. [Sézary syndrome showing a stable clinical course for more than four years after oral administration of etoposide and methotrexate].
    Hirayama Y; Nagai T; Ohta H; Koyama R; Matsunaga T; Sakamaki S; Niitsu Y
    Rinsho Ketsueki; 2000 Sep; 41(9):750-4. PubMed ID: 11070938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The Sézary syndrome].
    Ferreira F; Correia TM; Callabro L; Andrade J
    Acta Med Port; 1998 Dec; 11(12):1135-9. PubMed ID: 10192992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Extracorporeal photopheresis in the therapy of Sézary syndrome].
    Marschalkó M; Knobler R; Soós G; Berecz M; Pálóczy K; Rácz I
    Orv Hetil; 1993 Jun; 134(23):1253-7. PubMed ID: 8332344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral bexarotene in a therapy-resistant Sézary syndrome patient: observations on Sézary cell compartmentalization.
    el-Azhary RA; Bouwhuis SA
    Int J Dermatol; 2005 Jan; 44(1):25-8. PubMed ID: 15663654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Complication of topoisomerase II inhibitor-related acute promyelocytic leukemia with t(1;10) (q21;q26) in a patient with Sézary syndrome].
    Miyoshi N; Noda M
    Rinsho Ketsueki; 2006 May; 47(5):399-401. PubMed ID: 16784098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Successful combination chemotherapy including deoxycoformycin in a case of cutaneous T cell lymphoma].
    Kodama K; Yamada T; Kawakami K; Yasui K; Nomura T; Yamaoka M; Matsuo T
    Rinsho Ketsueki; 1996 Jan; 37(1):65-71. PubMed ID: 8683870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracorporeal photopheresis for the treatment of Sézary syndrome using a novel treatment protocol.
    Arulogun S; Prince HM; Gambell P; Lade S; Ryan G; Eaton E; McCormack C
    J Am Acad Dermatol; 2008 Oct; 59(4):589-95. PubMed ID: 18656282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurolymphomatosis associated with Sézary syndrome.
    Bezier M; Reguiaï Z; Delaby P; Laroche L; Saïd G; Bernard P; Grange F
    Arch Dermatol; 2009 Mar; 145(3):294-6. PubMed ID: 19289760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Small cell lung cancer with Sézary syndrome].
    Nakanishi M; Kubota Y; Hara H; Ueda M; Arimoto T; Iwasaki Y
    Nihon Kokyuki Gakkai Zasshi; 2009 Dec; 47(12):1135-40. PubMed ID: 20058693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sézary syndrome without erythroderma.
    Henn A; Michel L; Fite C; Deschamps L; Ortonne N; Ingen-Housz-Oro S; Marinho E; Beylot-Barry M; Bagot M; Laroche L; Crickx B; Maubec E
    J Am Acad Dermatol; 2015 Jun; 72(6):1003-9.e1. PubMed ID: 25981000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of late-stage Sézary syndrome with 2-Chlorodeoxyadenosine.
    Bouwhuis SA; el-Azhary RA; McEvoy MT; Gibson LE; Habermann TM; Witzig TE; Pittelkow MR
    Int J Dermatol; 2002 Jun; 41(6):352-6. PubMed ID: 12100691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sezary syndrome presenting with leonine facies and treated with low-dose subcutaneous alemtuzumab.
    Oliveira A; Lobo I; Alves R; Lima M; Selores M
    Dermatol Online J; 2011 Nov; 17(11):6. PubMed ID: 22136862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A woman with Sezary syndrome developed HTLV-1-associated myeloneuropathy. The reported case supports the theory of etiological connection].
    Roupe G
    Lakartidningen; 2003 Jul; 100(30-31):2441-2. PubMed ID: 12914139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy.
    Brennand S; Sutton VR; Biagi J; Trapani JA; Westerman D; McCormack CJ; Seymour JF; Kennedy G; Prince HM
    Br J Dermatol; 2005 Jun; 152(6):1199-205. PubMed ID: 15948982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atopic dermatitis-like pre-Sézary syndrome: role of immunosuppression.
    Sokołowska-Wojdyło M; Barańska-Rybak W; Cegielska A; Trzeciak M; Lugowska-Umer H; Gniadecki R
    Acta Derm Venereol; 2011 Sep; 91(5):574-7. PubMed ID: 21681350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained remission of Sézary syndrome.
    Bouwhuis SA; McEvoy MT; Davis MD
    Eur J Dermatol; 2002; 12(3):287-90. PubMed ID: 11978575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Sézary syndrome with bexarotene after IFNalpha and methotrexate failure.
    Bagot M
    Dermatol Clin; 2008 Jan; 26 Suppl 1():27-9. PubMed ID: 18405184
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haematodermic CD4+CD56+ neoplasm: complete remission after methotrexate-asparaginase treatment.
    Fontaine J; Thomas L; Balme B; Ronger-Savle S; Traullé C; Petrella T; Dalle S
    Clin Exp Dermatol; 2009 Jul; 34(5):e43-5. PubMed ID: 19508475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.